Where is YolTech located?

YolTech is headquartered in Shanghai, China.

Who is the current CEO of YolTech?

Yuxuan Wu of YolTech. They have also founded 1 company.

Is YolTech a funded company?

YolTech is a funded company, having raised a total of $59.1M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of YolTech?

YolTech's latest funding was a $***** Series B round on Sep 11, 2025, with participation from 1 investor.

Where does YolTech rank among its competitors?

YolTech ranks 160th amongst 1229 active competitors, of which 447 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was YolTech, which secured $45M in Sep, 2025.

Who are the top competitors of YolTech?

YolTech's top competitors include Alnylam, Spark Therapeutics and Sana Biotechnology. Among them, YolTech secured the most recent funding round in September, 2025.

YolTech - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.

Website: www.yoltx.com/
Email ID: *****@yoltx.com
Phone Number: +86 **********

Key Metrics

Founded Year

2021

Location

Shanghai, China

Stage

Series B

Total Funding

$59.1M in 4 rounds

Latest Funding Round

Series B, Sep 11, 2025, $*****

Investors

Decheng Capital & 4 more

Ranked

160^th among 1229 active competitors

Similar Companies

Alnylam & 1505 more

View YolTech's full profile

YolTech has raised a total funding of $59.1M over 4 rounds. Its latest funding round was a Series B round on Sep 11, 2025 for $*****. 1 investor participated in its latest round. YolTech has 5 institutional investors.

Here is the list of recent funding rounds of YolTech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 11, 2025	7199124	Series B	1475905	2567549	9483067	4021603
Nov 30, 2023	9332747	Series A	2887673	3266315	9076580	Guangzhou Industrial Investment Group & 1 more
Feb 25, 2022	4843838	Angel	7518138	2549525	8812822	K2VC

Access funding benchmarks and valuations. Sign up today!

View details of YolTech's funding rounds and investors

The founders of YolTech is Yuxuan Wu. Yuxuan Wu is the CEO of YolTech.

Here are the details of YolTech's key team members:

Yuxuan Wu: Founder & CEO of YolTech.

View details of YolTech's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of YolTech include Alnylam, Spark Therapeutics and Sana Biotechnology. Here is the list of Top 10 competitors of YolTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Baillie Gifford & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Forbion & 20 others	72/100
5th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, Healthcap & 9 others	71/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Google Ventures & 18 others	71/100
7th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Google Ventures, Third Rock Ventures & 15 others	70/100
8th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
9th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
10th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
160th	YolTech 2021, Shanghai (China), Series B	Developer of gene editing and LNP delivery platforms for therapeutics	$59.1M	Decheng Capital, Astrazeneca & 3 others	55/100